|  |
| --- |
|  |
| Book Name: | [New Advances in Business, Management and Economics](https://www.bookpi.org/bookstore/product/new-advances-in-business-management-and-economics-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_4347** |
| Title of the Manuscript:  | **Pre TRIPS, Post TRIPS Patent Regime and the Indian Pharmaceutical Industry: An Empirical Study** |
| Type of the Article | **BOOK CHAPTER** |

|  |
| --- |
| PART 1: Comments |
|  | Reviewer’s comment | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | **The manuscript deals with the impact of the change in Patent Law in India. Author(s) evaluate(s) various financial parameters of the leading Indian pharmaceutical companies and concluded that TRIPS agreement had a positive effect on the Indian Pharmaceutical industries promotion.**  |  |
| **Is the title of the article suitable?****(If not please suggest an alternative title)** | **Do Aurbindo, Cipla, Lupin, Ranbaxy, and Dabur companies represent the Indian pharmaceutical industry? If Yes, the title is informative. If No, the title should be changed to: Pre TRIPS, Post TRIPS Patent Regime and the Indian Big Pharma companies: An Empirical Study. A comparative study for Indian pharmaceutical companies is necessary.**  |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | **Yes.** |  |
| **Is the manuscript scientifically, correct? Please write here.**  | **Yes. The bases of the study design, research methodology, results and conclusion is scientifically correct. However, “Discussin Section” is absent.** |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.** | **The references are not sufficient for a book chapter. Additional references are required for supporting of the data. For example: from international sources. Also, is it possible updating of the data from 2011 to 2024?****References 10 to 14 should be cited in the text.** |  |
| Is the language/English quality of the article suitable for scholarly communications? | **There are some avoidable punctuation and grammatical errors. The manuscript should be revised in this regard. Also, both American or British styles is seen in writing of the manuscript. The manuscript should be uniformed.**  |  |
| Optional/General comments | **1.Page 2, column 1, Line 1: What is the meaning “In” in “In1”? Also in other references? Isn't Alam et al. better?****2.Page 2, column 2, paragraph 2, Line 2: “CSR”. If an abbreviation has appeared in the text, it should be defined at the first mention.****3.Page 3, column 2, Line 1-2: The sentence is repetitive. Why? This issue is seen in other explanation of the figures.****1.Page 1, column 1, Line 12: One of the important points in the implementation of the TRIPS Agreement is the equitable access to medicines. TRIPS may have played a positive role in the growth of the Indian pharmaceutical industry, however, equitable access to medicines for the Indian people requires a separate study which is beyond the scope of this manuscript. This sentence should be deleted.****2.Page 3, column 1, Line 4: The aoyhor(s) stated that statistical tools was performed for data analysis. What are the results? For example, Mean ± SD or Error bars to indicate the uncertainty.****3.Page 6, column 1, “Recommendation Section”, paragraph 2: There is no discussion about relationship between Good Manufacturing Practice (GMP) and Pre TRIPS, Post TRIPS Patent Regime in India. Where there is not discussion, can author(s) recommend this topic? In other words, how aothor(s) find the impact of GMP on the Indian Pharmaceutical Industry in the Pre TRIPS and Post TRIPS Patent Regime period in India?****4.Page 6, column 1, “Recommendation Section”, paragraph 3: The reviewer does not found any trlationship between this recommendation and the subject of the manuscript.****5.One of the highlights of the results is the difference in financial parameters for Cipla compared to other Indian big pharma companies. There is no discussion for these differences.****6.“Discussin Section” is absent.** |  |

|  |
| --- |
| **PART 2:**  |
|  | **Reviewer’s comment** | **Author’s comment *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*** |
| **Are there ethical issues in this manuscript?**  | ***(If yes, Kindly please write down the ethical issues here in details)*** |  |

|  |
| --- |
| **Reviewer Details:** |
| **Name:** | **Say-yed Hesameddin Tafreshi** |
| **Department, University & Country** | **Pasteur Institute of Iran, Iran** |